Office: Basil Hetzel Institute for Translational Health Research, 37a Woodville Road, Woodville South, SA 5011
I head the Tumour Microenvironment Laboratory at the Centre for Cancer Biology, formed by an alliance between SA Pathology and the University of South Australia, and the Cancer Mechanotherapies Laboratory at the Basil Hetzel Institute for Translational Health Research. Our research focuses on understanding the tumour microenvironment, the support structure that cancers build around themselves. Current cancer therapies rely heavily on directly targeting aberrant tumour cell behaviour resulting from genetic mutations. Such approaches frequently elicit therapy resistance owing the ability of tumour cells to acquire further mutations enabling them to evade therapy. However, tumours are critically dependent upon their stromal cell component,... Read more
About me
I head the Tumour Microenvironment Laboratory at the Centre for Cancer Biology, formed by an alliance between SA Pathology and the University of South Australia, and the Cancer Mechanotherapies Laboratory at the Basil Hetzel Institute for Translational Health Research. Our research focuses on understanding the tumour microenvironment, the support structure that cancers build around themselves. Current cancer therapies rely heavily on directly targeting aberrant tumour cell behaviour resulting from genetic mutations. Such approaches frequently elicit therapy resistance owing the ability of tumour cells to acquire further mutations enabling them to evade therapy. However, tumours are critically dependent upon their stromal cell component, which are populated by genetically normal cells. Targeting stromal cell behaviour can reduce the potential for therapy resistance, as stromal cells are typically genetically stable. Our research seeks to identify the mechanisms by which tumours remodel their microenvironments to promote tumour progression, with a view to uncovering new approaches to interfering with this process.
I completed my Bachelor’s degree with Honours in Biochemistry and Molecular Biology at the Australian National University, Canberra. I then moved to Melbourne to conduct Ph.D. research at the Ludwig Institute for Cancer Research, in the laboratory of Prof. Matthias Ernst. Here I studied the function of DNA methyltransferase dysregulation in intestinal cancers, showing that increased DNA methyltransferase activity has a causal role in tumour progression.
Moving to the Beatson Institute for Cancer Research, UK in 2006 to join the laboratory of Prof. Michael Olson as a postdoctoral scientist, I began working on the cytoskeletal signalling pathways that have absorbed my interest over the past 10 years, and laid the foundation for my current research programme. During this time, I established novel models of conditionally active cytoskeletal signalling to demonstrate that these pathways regulate tissue-level mechanical changes that promote tumour growth and progression.
In 2011, I won a Florey Fellowship to move back to Australia and in 2012 set up the Tumour Microenvironment Laboratory at the Centre for Cancer Biology with funding from a National Health and Medical Research Council New Investigator grant. I was awarded an ARC Future Fellowship in 2012.
About me
About me
Date | Title |
---|---|
26/05/2020 |
Channel 7 interview and story regarding tumour microenvironment in breast cancer, https://7news.com.au/technology/sa-scientists-find-breast-cancer-link-c-1060005 |
26/05/2020 |
Channel 9 interview and story regarding tumour microenvironment in breast cancer, https://twitter.com/i/status/1265204788507090944 |
06/09/2019 |
Michael Samuel speaks about research at the Centre for Cancer Biology, https://www.youtube.com/watch?v=uD_IYX3YF9o |
21/12/2015 |
AM, ABC Radio National: Faster wound healing from accidental discovery, http://www.abc.net.au/am/content/2015/s4376886.htm |
21/12/2015 |
ABC News website: Unexpected discovery by Adelaide researchers could halve healing time for chronic wounds, http://www.abc.net.au/news/2015-12-22/discovery-with-the-potential-to-heal-wounds-faster/7047036 |
21/12/2015 |
A new approach to speed up wound healing: ABC News 24, https://www.youtube.com/watch?v=EzVnyXHbR9A&list=PL0644D2DA3A36AD3C&index=18 |
21/12/2015 |
The key to speeding up the body’s healing?, http://www.adelaidenow.com.au/news/south-australia/researchers-discover-link-between-inhibiting-1433zeta-protein-and-faster-wound-healing/news-story/89dca902ef8e46f22503ae3783548585 |
About me
PhD: Medicine, Dentistry and Health Sciences The University of Melbourne
Bachelor of Science (Honours) The Australian National University
2006 - 2011: Research Scientist, Beatson Institute for Cancer Research, UK
2012 - 2014: Lab Head, Tumour Microenvironment Laboratory, SA Pathology and University of Adelaide, Australia
The mechanism of tumour promotion by the Rho-ROCK signalling pathway
We have demonstrated that activating ROCK within the epidermis leads to hyper-proliferation of keratinocytes and promotes tumour formation in a murine squamous cell carcinoma model. This mechanism links ROCK activation and changes to cell tension and tissue stiffness to integrin signalling and the Wnt pathway (Cancer Cell 19(6):776-91). These results strongly support the hypothesis that signalling through ROCK plays a key role in tumour progression.
Recently, we have demonstrated that these mechanotransduction pathways are a relevant feature of human cutaneous SCC (Am. J. Pathol. 183(3):930-7) and that druggable negative regulators of mechanotransduction pathways... Read more
Research
Excludes commercial-in-confidence projects.
Targeting lethal metastases: finding new targets in the tumour/microenvironment interface , NHMRC - Synergy Grants, 01/01/2024 - 31/12/2028
Dual epithelial and stromal targeting in breast cancer using the phase II ROCK2 inhibitor KD025 guided by intravital imaging technology., US Army, Research, Development and Engineering Command, 01/01/2022 - 31/12/2024
Targeting ROCK-mediated microenvironment changes as a novel colorectal cancer therapy, The Hospital Research Foundation, 01/04/2018 - 17/09/2021
How does ROCK `education' of fibroblasts drive neoplastic progression in the breast?, NHMRC - Project Grant, 01/01/2018 - 31/12/2020
Defining the function of ROCK in establishing a tumour-promoting microenvironment, NHMRC - Project Grant, 01/01/2016 - 31/12/2019
Using miR-200 to find new therapeutic targets for neuroblastoma, NHMRC - Project Grant, 01/01/2017 - 31/12/2019
Defining the mechanisms regulating tissue mechano-reciprocity in wound healing, NHMRC - Project Grant, 01/01/2016 - 31/12/2018
Mast cells are key negative regulators of skin tumourigenesis, NHMRC - Project Grant, 01/01/2014 - 31/12/2017
How do mechanical cues regulate tissue renewal and tumour progression?, ARC - Future Fellowship, 01/01/2014 - 31/12/2016
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2024 |
Open access
|
2022 |
Open access
30
24
|
2022 |
Open access
9
|
2020 |
50
49
|
2015 |
Open access
30
23
25
|
Year | Output |
---|---|
2021 |
Open access
9
|
2018 |
1
|
2010 |
7
6
|
Year | Output |
---|---|
2024 |
Open access
|
2024 |
Open access
1
|
2024 |
Open access
|
2024 |
Open access
|
2023 |
4
3
4
|
2023 |
Open access
2
|
2023 |
1
14
|
2023 |
Open access
1
4
|
2022 |
Open access
30
24
|
2022 |
Open access
17
17
10
|
2022 |
Open access
2
2
15
|
2022 |
Open access
9
|
2021 |
Open access
14
15
60
|
2021 |
Open access
28
28
143
|
2021 |
Open access
22
16
5
|
2020 |
Open access
12
11
38
|
2020 |
Open access
13
14
8
|
2020 |
50
49
|
2020 |
Open access
17
16
6
|
2019 |
Open access
40
36
4
|
2019 |
Open access
19
18
5
|
2019 |
104
97
9
|
2018 |
Open access
36
12
|
2018 |
Open access
300
293
78
|
2018 |
Open access
33
26
14
|
2018 |
Open access
259
253
7
|
2017 |
Open access
17
16
3
|
2017 |
Open access
74
68
39
|
2017 |
Open access
99
97
13
|
2017 |
Open access
205
197
109
|
2016 |
Open access
24
3
|
2016 |
Open access
7
|
2016 |
Open access
50
47
|
2016 |
Open access
9
8
5
|
2015 |
Open access
23
22
|
2015 |
Open access
30
23
25
|
2015 |
Open access
32
27
3
|
2014 |
Open access
15
16
|
2014 |
Open access
97
87
33
|
2013 |
Open access
39
33
|
2013 |
Open access
35
33
|
2012 |
Open access
311
293
|
2011 |
Open access
66
65
|
2011 |
Open access
441
423
|
2011 |
Open access
31
28
|
2010 |
Open access
80
70
|
2009 |
20
18
|
2009 |
34
30
|
Patents:
1. MODULATORS OF 14-3-3 FUNCTIONALITY AND USES THEREOF WO2011120082 A1
Research
The mechanism of tumour promotion by the Rho-ROCK signalling pathway
We have demonstrated that activating ROCK within the epidermis leads to hyper-proliferation of keratinocytes and promotes tumour formation in a murine squamous cell carcinoma model. This mechanism links ROCK activation and changes to cell tension and tissue stiffness to integrin signalling and the Wnt pathway (Cancer Cell 19(6):776-91). These results strongly support the hypothesis that signalling through ROCK plays a key role in tumour progression.
Recently, we have demonstrated that these mechanotransduction pathways are a relevant feature of human cutaneous SCC (Am. J. Pathol. 183(3):930-7) and that druggable negative regulators of mechanotransduction pathways exist (Dev. Cell 35(6): 759-774). We are currently working on identifying the mechanism by which the activation of Rho-ROCK signalling within tumour cells promotes tumour progression. We are now working on new approaches to enhance the negative regulation of mechanical signalling as novel anti-cancer therapies.
How does the Rho-ROCK pathway generate a permissive tumour microenvironment?
Our laboratory has recently shown that the Rho-ROCK pathway is progressively activated within fibroblasts, macrophages and several other cell types within the tumour microenvironment, during tumour progression. This change is accompanied by increased generation of ECM components, including collagen, fibronectin and periostin, in a ROCK-dependent manner. Taken together, these results strongly suggest that ROCK activation remodels the tissue microenvironment to promote tumour progression. This project seeks to identify the mechanisms by which activation of ROCK generates a tumour-permissive microenvironment, using our conditionally active ROCK mouse models.
How is the Rho-ROCK pathway regulated during wound healing?
We have shown that wound healing is much quicker when ROCK is activated in models within which we can control the activation of ROCK at will (Dev. Cell 35(6): 759-774). Interestingly, in patient wound samples ROCK is activated at wound margins in rapidly healing wounds and the converse is true of chronic wounds that heal slowly. We are working to identify the mechanism by which ROCK activation regulates the wound healing process with a view to identifying therapeutic targets to promote the healing of chronic wounds.
Research
Details | Registry | Status |
---|---|---|
Modulators of 14-3-3 functionality and uses thereof Woodcock, Joanna; Lopez, Angel; Pitson, Stuart M; Samuel, Michael S; Coolen, Carl |
United States | Filed |
Modulators of 14-3-3 functionality and uses thereof Woodcock, Joanna; Lopez, Angel; Pitson, Stuart; Samuel, Michael; Coolen, Carl |
WO | Filed |
Interviews with Channels 7, 9 and 10, May 2020: Highlights our new discovery that cancer secrete a factor called CRELD2 that causes normal cells called fibroblasts to work with the cancer to accelerate progression of the disease. Blocking CRELD2 stops cancer progression.
Health Forum, University of South Australia 2016: Member of panel discussion on health issues associated with sport - to particularly highlight wound management advances.
Interview with ABC News 24, December 2015: Highlights our new discovery that opens the way for new therapies to accelerate wound healing.
Corporate Event at Tour Down Under, 2015: Member of panel discussion to highlight the research strengths of the Centre for Cancer Biology and University of South Australia.
Patient Education Campaign, SA Pathology 2012: Designed a poster for display in SA Pathology's Patient Centres, titled "What is Cancer?".
External engagement & recognition
Organisation | Country |
---|---|
Abo Academy University | FINLAND |
Beatson Institute for Cancer Research | UNITED KINGDOM |
Cancer Research Uk | UNITED KINGDOM |
Cardiff University | UNITED KINGDOM |
Central Adelaide Local Health Network Incorporated | AUSTRALIA |
Children's Cancer Institute Australia | AUSTRALIA |
Children's Cancer Institute Australia for Medical Research | AUSTRALIA |
City University Of New York, Queens College | UNITED STATES |
Edinburgh Cancer Research Centre | UNITED KINGDOM |
Flinders University | AUSTRALIA |
Garvan Institute of Medical Research | AUSTRALIA |
Genentech | UNITED STATES |
Hubrecht Institute | NETHERLANDS |
Islamic Azad University | IRAN |
John Wiley & Sons (United Kingdom) | UNITED KINGDOM |
John Wiley & Sons (United States) | UNITED STATES |
Ludwig Maximilian University of Munich | GERMANY |
Mashhad University of Medical Sciences | IRAN |
McGill University | CANADA |
Monash University | AUSTRALIA |
National University of Malaysia | MALAYSIA |
Netherlands Cancer Institute | NETHERLANDS |
QIMR Berghofer Medical Research Institute | AUSTRALIA |
Queen Mary University of London | UNITED KINGDOM |
Queensland University of Technology | AUSTRALIA |
RMIT University | AUSTRALIA |
Royal Adelaide Hospital | AUSTRALIA |
Royal Alexandra Hospital for Children | AUSTRALIA |
Royal Melbourne Hospital | AUSTRALIA |
SA Pathology | AUSTRALIA |
Sapporo Medical University | JAPAN |
Stanford University | UNITED STATES |
Swiss Federal Institute of Technology Lausanne | SWITZERLAND |
The Kinghorn Cancer Centre | AUSTRALIA |
The Warren Alpert Medical School of Brown University | UNITED STATES |
Toronto Metropolitan University | CANADA |
University College London | UNITED KINGDOM |
University of Adelaide | AUSTRALIA |
University of Bath | UNITED KINGDOM |
University of Bristol | UNITED KINGDOM |
University of California | UNITED STATES |
University of Dundee | UNITED KINGDOM |
University of Edinburgh | UNITED KINGDOM |
University of Glasgow | UNITED KINGDOM |
University of Melbourne | AUSTRALIA |
University of New South Wales | AUSTRALIA |
University of Queensland | AUSTRALIA |
University of Science Malaysia (Malaysia) | MALAYSIA |
University of South Australia | AUSTRALIA |
University of Sydney | AUSTRALIA |
Vrije University Brussel | BELGIUM |
Walter and Eliza Hall Institute of Medical Research | AUSTRALIA |
Women's and Children's Health Network | AUSTRALIA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
Barry Preston AwardMatrix Biology Society of Australia and New Zealand |
2021 |
ANZSCDB Emerging Leader Award 2020Australia and New Zealand Society of Cell and Developmental Biology |
2020 |
Future FellowshipAustralian Research Council (ARC) |
2018 |
Future FellowshipAustralian Research Council (ARC) |
2017 |
Future FellowshipAustralian Research Council (ARC) |
2016 |
Future FellowshipAustralian Research Council (ARC) |
2015 |
Future FellowshipAustralian Research Council (ARC) |
2014 |
Future FellowshipAustralian Research Council (ARC) |
2013 |
Future FellowshipAustralian Research Council (ARC) |
2012 |
Beatson Postdoctoral FellowBeatson Institute for Cancer Research, Scotland, United Kingdom |
2011 |
Beatson Postdoctoral FellowshipBeatson Institute for Cancer Research |
2011 |
Florey FellowUniversity of Adelaide |
2011 |
Beatson Postdoctoral FellowBeatson Institute for Cancer Research, Scotland, United Kingdom |
2010 |
Beatson Postdoctoral FellowshipBeatson Institute for Cancer Research |
2010 |
Beatson Postdoctoral FellowBeatson Institute for Cancer Research, Scotland, United Kingdom |
2009 |
Beatson Postdoctoral FellowshipBeatson Institute for Cancer Research |
2009 |
Beatson Postdoctoral FellowBeatson Institute for Cancer Research, Scotland, United Kingdom |
2008 |
Beatson Postdoctoral FellowshipBeatson Institute for Cancer Research |
2008 |
2021 Barry Preston Award - Awarded by the Matrix Biology Society of Australia and New Zealand, the Barry Preston Award recognises an outstanding leader in the matrix biology field distinguished by a sustained record of achievement, commitment to mentoring junior researchers and exceptional communication skills (reference).
2020 Emerging Leader Award - Awarded by the Australia and New Zealand Society for Cell and Developmental Biology, the ELA was established to encourage and support emerging investigators who are at the stage of building independent careers in our disciplines in Australia and New Zealand. The award will be an imprimatur of scientific accomplishment. The principal criteria will be the quality of the candidate's research and evidence of ability to sustain an independent career (reference).
While I primarily work as a researcher, I regularly undertake guest lecturing at both the University of South Australia and University of Adelaide, speaking about my laboratory's research into the tumour microenvironment.
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
Advancing a novel biomarker for pancreatic cancer | Current |
Characterisation of extracellular matrix composition across the human brain and applications in brain organoid vascularisation | Current |
Revealing the role of ICAM1 in breast cancer progression | Current |
Targeting the tumour vasculature in melanoma for a more effective immune response and improved survival | Current |
The role for caspase-2 in mammary development and fat biology | Current |
Understanding chemoresistance mechanisms in triple negative breast cancer | Current |
Understanding How Cancers Modify the Functional Characteristics of the Tumour Extra-cellular Matrix | Current |
Understanding how the epigenetic field effect exerted by cancers upon their microenvironment promotes tumour progression | Current |
Understanding how the epigenetic field effect exerted by cancers upon their microenvironment promotes tumour progression | Current |
Understanding how the epigenetic field effect exerted by cancers upon their microenvironment promotes tumour progression | Current |
Artificial intelligence and brain cancer survival rate based on tumour microenvironment characteristics | Completed |
Atomic force microscopy and spectroscopic studies of crosslinking induced changes in the extracellular matrix that influence nanomechanical properties | Completed |
Desmoglein-2 as a regulator of pancreatic ductal adenocarcinoma progression | Completed |
Investigating the roles of 14-3-3zeta in the mammary tumour microenvironment | Completed |
Targeting sphingolipid metabolism in proteasome inhibitor-resistant multiple myeloma | Completed |